RxDoctor Payments Data

Ariel Graham

Primary Care · Rayville, LANPI 1710414719

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 384 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,317in general payments, 2019–2025

Across 384 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$527
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$426
  • Merck$419
  • Bayer$414
  • Amgen$353
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,317100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,317 in reported general payments places this provider in the 90th percentile of 106 primary care providers in Louisiana.

See all primary care providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine20$125,972
MounjaroTirzepatide105$111,238
JardianceEmpagliflozin56$57,517
LinzessLinaclotide64$39,435
OzempicSemaglutide32$36,678
RexultiBrexpiprazole17$30,689
VraylarCariprazine Hcl19$30,506
KerendiaFinerenone13$21,428
XareltoRivaroxaban30$21,153
FarxigaDapagliflozin Propanediol18$20,202
EliquisApixaban23$18,958
Synjardy XrEmpagliflozin/Metformin Hcl18$18,582
EntrestoSacubitril/Valsartan16$18,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,901
Repatha SyringeEvolocumab18$9,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$239$125,97220 claims
Lilly USA, LLCMounjaro$116$111,238105 claims
Boehringer IngelheimJardiance, Synjardy Xr$219$76,09974 claims
AbbVieLinzess, Vraylar$1,169$69,94083 claims
Novo NordiskOzempic$208$36,67832 claims
Otsuka America Pharmaceutical, Inc.Rexulti$257$30,68917 claims
GSKTrelegy Ellipta, Anoro Ellipta$124$21,98737 claims
BayerKerendia$414$21,42813 claims
Johnson & JohnsonXarelto$156$21,15330 claims
AstraZenecaFarxiga$527$20,20218 claims
PfizerEliquis$217$18,95823 claims
NovartisEntresto$17$18,02216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 106 primary care providers in Louisiana.

Other primary care in Rayville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →